Cargando…
The Efficacy of Mesenchymal Stem Cell Therapies in Rodent Models of Multiple Sclerosis: An Updated Systematic Review and Meta-Analysis
Studies have demonstrated the potential of mesenchymal stem cell (MSC) administration to promote functional recovery in preclinical studies of multiple sclerosis (MS), yet the effects of MSCs on remyelination are poorly understood. We wished to evaluate the therapeutic effects of MSCs on functional...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427822/ https://www.ncbi.nlm.nih.gov/pubmed/34512632 http://dx.doi.org/10.3389/fimmu.2021.711362 |
_version_ | 1783750251962695680 |
---|---|
author | He, Jialin Huang, Yan Liu, Jianyang Lan, Ziwei Tang, Xiangqi Hu, Zhiping |
author_facet | He, Jialin Huang, Yan Liu, Jianyang Lan, Ziwei Tang, Xiangqi Hu, Zhiping |
author_sort | He, Jialin |
collection | PubMed |
description | Studies have demonstrated the potential of mesenchymal stem cell (MSC) administration to promote functional recovery in preclinical studies of multiple sclerosis (MS), yet the effects of MSCs on remyelination are poorly understood. We wished to evaluate the therapeutic effects of MSCs on functional and histopathological outcomes in MS; therefore, we undertook an updated systematic review and meta-analysis of preclinical data on MSC therapy for MS. We searched mainstream databases from inception to July 15, 2021. Interventional studies of therapy using naïve MSCs in in vivo rodent models of MS were included. From each study, the clinical score was extracted as the functional outcome, and remyelination was measured as the histopathological outcome. Eighty-eight studies published from 2005 to 2021 met the inclusion criteria. Our results revealed an overall positive effect of MSCs on the functional outcome with a standardized mean difference (SMD) of −1.99 (95% confidence interval (CI): −2.32, −1.65; p = 0.000). MSCs promoted remyelination by an SMD of −2.31 (95% CI: −2.84, −1.79; p = 0.000). Significant heterogeneity among studies was observed. Altogether, our meta-analysis indicated that MSC administration improved functional recovery and promoted remyelination prominently in rodent models of MS. |
format | Online Article Text |
id | pubmed-8427822 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84278222021-09-10 The Efficacy of Mesenchymal Stem Cell Therapies in Rodent Models of Multiple Sclerosis: An Updated Systematic Review and Meta-Analysis He, Jialin Huang, Yan Liu, Jianyang Lan, Ziwei Tang, Xiangqi Hu, Zhiping Front Immunol Immunology Studies have demonstrated the potential of mesenchymal stem cell (MSC) administration to promote functional recovery in preclinical studies of multiple sclerosis (MS), yet the effects of MSCs on remyelination are poorly understood. We wished to evaluate the therapeutic effects of MSCs on functional and histopathological outcomes in MS; therefore, we undertook an updated systematic review and meta-analysis of preclinical data on MSC therapy for MS. We searched mainstream databases from inception to July 15, 2021. Interventional studies of therapy using naïve MSCs in in vivo rodent models of MS were included. From each study, the clinical score was extracted as the functional outcome, and remyelination was measured as the histopathological outcome. Eighty-eight studies published from 2005 to 2021 met the inclusion criteria. Our results revealed an overall positive effect of MSCs on the functional outcome with a standardized mean difference (SMD) of −1.99 (95% confidence interval (CI): −2.32, −1.65; p = 0.000). MSCs promoted remyelination by an SMD of −2.31 (95% CI: −2.84, −1.79; p = 0.000). Significant heterogeneity among studies was observed. Altogether, our meta-analysis indicated that MSC administration improved functional recovery and promoted remyelination prominently in rodent models of MS. Frontiers Media S.A. 2021-08-26 /pmc/articles/PMC8427822/ /pubmed/34512632 http://dx.doi.org/10.3389/fimmu.2021.711362 Text en Copyright © 2021 He, Huang, Liu, Lan, Tang and Hu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology He, Jialin Huang, Yan Liu, Jianyang Lan, Ziwei Tang, Xiangqi Hu, Zhiping The Efficacy of Mesenchymal Stem Cell Therapies in Rodent Models of Multiple Sclerosis: An Updated Systematic Review and Meta-Analysis |
title | The Efficacy of Mesenchymal Stem Cell Therapies in Rodent Models of Multiple Sclerosis: An Updated Systematic Review and Meta-Analysis |
title_full | The Efficacy of Mesenchymal Stem Cell Therapies in Rodent Models of Multiple Sclerosis: An Updated Systematic Review and Meta-Analysis |
title_fullStr | The Efficacy of Mesenchymal Stem Cell Therapies in Rodent Models of Multiple Sclerosis: An Updated Systematic Review and Meta-Analysis |
title_full_unstemmed | The Efficacy of Mesenchymal Stem Cell Therapies in Rodent Models of Multiple Sclerosis: An Updated Systematic Review and Meta-Analysis |
title_short | The Efficacy of Mesenchymal Stem Cell Therapies in Rodent Models of Multiple Sclerosis: An Updated Systematic Review and Meta-Analysis |
title_sort | efficacy of mesenchymal stem cell therapies in rodent models of multiple sclerosis: an updated systematic review and meta-analysis |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427822/ https://www.ncbi.nlm.nih.gov/pubmed/34512632 http://dx.doi.org/10.3389/fimmu.2021.711362 |
work_keys_str_mv | AT hejialin theefficacyofmesenchymalstemcelltherapiesinrodentmodelsofmultiplesclerosisanupdatedsystematicreviewandmetaanalysis AT huangyan theefficacyofmesenchymalstemcelltherapiesinrodentmodelsofmultiplesclerosisanupdatedsystematicreviewandmetaanalysis AT liujianyang theefficacyofmesenchymalstemcelltherapiesinrodentmodelsofmultiplesclerosisanupdatedsystematicreviewandmetaanalysis AT lanziwei theefficacyofmesenchymalstemcelltherapiesinrodentmodelsofmultiplesclerosisanupdatedsystematicreviewandmetaanalysis AT tangxiangqi theefficacyofmesenchymalstemcelltherapiesinrodentmodelsofmultiplesclerosisanupdatedsystematicreviewandmetaanalysis AT huzhiping theefficacyofmesenchymalstemcelltherapiesinrodentmodelsofmultiplesclerosisanupdatedsystematicreviewandmetaanalysis AT hejialin efficacyofmesenchymalstemcelltherapiesinrodentmodelsofmultiplesclerosisanupdatedsystematicreviewandmetaanalysis AT huangyan efficacyofmesenchymalstemcelltherapiesinrodentmodelsofmultiplesclerosisanupdatedsystematicreviewandmetaanalysis AT liujianyang efficacyofmesenchymalstemcelltherapiesinrodentmodelsofmultiplesclerosisanupdatedsystematicreviewandmetaanalysis AT lanziwei efficacyofmesenchymalstemcelltherapiesinrodentmodelsofmultiplesclerosisanupdatedsystematicreviewandmetaanalysis AT tangxiangqi efficacyofmesenchymalstemcelltherapiesinrodentmodelsofmultiplesclerosisanupdatedsystematicreviewandmetaanalysis AT huzhiping efficacyofmesenchymalstemcelltherapiesinrodentmodelsofmultiplesclerosisanupdatedsystematicreviewandmetaanalysis |